Human infections caused by Brevibacterium casei, formerly CDC groups B-1 and B-3

Prior research has shown that CDC coryneform groups B-1 and B-3 are often misclassified. These groups include bacteria with biochemical similarities but unclear clinical relevance. It was already known that Brevibacterium species are typically considered nonpathogenic. No prior work had resolved whether these CDC groups contain clinically significant pathogens. This gap motivated a detailed taxonomic and clinical analysis of 41 clinical isolates. The uncertainty around their classification and potential pathogenicity created a need for systematic comparison. Researchers needed to determine if these isolates belonged to known Brevibacterium species. The lack of clear clinical data on these isolates highlighted the importance of this study.

The aim of this work was to classify 41 clinical isolates from CDC coryneform groups B-1 and B-3. The researchers sought to determine their taxonomic placement within the Brevibacterium genus. They focused on biochemical and genomic characteristics to identify species. The study aimed to clarify whether these isolates are pathogenic or nonpathogenic. By comparing isolates to known Brevibacterium species, the team aimed to resolve taxonomic ambiguity. The motivation came from the lack of clinical data on these isolates. Researchers wanted to assess if B. casei could cause infections. This work addresses a gap in understanding the clinical significance of these bacteria.

The team used biochemical testing to compare the isolates. They analyzed cell wall sugars, amino acids, and fatty acids. DNA relatedness was assessed using hybridization techniques. The isolates were compared to type strains of Brevibacterium species. Phenotypic and genotypic data were used to classify the isolates. Researchers identified 22 isolates as B. casei. Five isolates formed a genomospecies within the same genus. The remaining isolates were genetically distinct but not fully identified.

Twenty-two isolates were identified as B. casei. Five isolates formed a genomospecies within Brevibacterium. The remaining isolates were genetically diverse but distinct from B. casei. Eleven isolates were recovered from blood cultures. Two isolates each came from cerebrospinal and pleural fluids. At least five isolates were from multiple cultures of the same body fluid. These findings suggest B. casei may be pathogenic. Prior studies had not reported clinical isolates of B. casei.

The authors propose that B. casei may be a pathogen. Their findings suggest clinical isolates of B. casei exist. The isolates were recovered from multiple body fluids, indicating potential virulence. The researchers suggest B. casei should be reconsidered as nonpathogenic. The genomospecies identified may represent a new Brevibacterium species. These results challenge prior assumptions about Brevibacterium taxonomy. The clinical relevance of these isolates remains to be fully understood. Further studies are needed to confirm these findings.